Eli Lilly Crecimiento futuro

Future controles de criterios 5/6

Eli Lilly se prevé un crecimiento anual de los beneficios y los ingresos de 27.2% y 15.4% respectivamente. Se prevé que el BPA sea de grow en 27.1% al año. Se prevé que la rentabilidad de los fondos propios sea de 63.5% en 3 años.

Información clave

27.2%

Tasa de crecimiento de los beneficios

27.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	20.0%
Tasa de crecimiento de los ingresos	16.0%
Rentabilidad financiera futura	70.7%
Cobertura de analistas	Good
Última actualización	19 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:LLY - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	60,672	20,578	17,469	18,197	23
12/31/2025	51,289	15,788	13,259	14,962	27
12/31/2024	41,361	10,893	8,386	11,091	27
12/31/2023	34,124	5,240	-1,548	4,240	N/A
9/30/2023	32,073	4,988	1,374	5,713	N/A
6/30/2023	29,516	6,498	3,211	5,741	N/A
3/31/2023	27,691	5,687	3,786	6,292	N/A
12/31/2022	28,541	6,245	4,696	7,586	N/A
9/30/2022	29,240	6,033	5,404	8,080	N/A
6/30/2022	29,071	5,692	4,950	7,494	N/A
3/31/2022	29,323	6,129	5,824	8,086	N/A
12/31/2021	28,318	5,582	5,604	7,366	N/A
9/30/2021	27,759	5,972	4,621	6,919	N/A
6/30/2021	26,726	6,071	4,837	7,095	N/A
3/31/2021	25,486	6,093	5,565	7,815	N/A
12/31/2020	24,540	6,194	4,471	6,500	N/A
9/30/2020	23,214	5,573	5,112	6,648	N/A
6/30/2020	22,950	5,618	4,890	6,352	N/A
3/31/2020	23,087	5,533	3,684	4,908	N/A
12/31/2019	22,320	4,638	3,483	4,837	N/A
9/30/2019	21,843	4,264	2,671	4,322	N/A
6/30/2019	21,673	4,103	3,324	4,933	N/A
3/31/2019	21,622	2,545	2,217	5,399	N/A
12/31/2018	21,493	3,151	2,506	5,525	N/A
9/30/2018	22,016	372	2,100	5,819	N/A
6/30/2018	22,368	-166	1,711	5,579	N/A
3/31/2018	22,607	1,074	3,481	5,712	N/A
12/31/2017	19,974	-86	3,452	5,616	N/A
9/30/2017	22,471	2,225	N/A	5,879	N/A
6/30/2017	22,005	2,447	N/A	5,659	N/A
3/31/2017	21,585	2,187	N/A	5,410	N/A
12/31/2016	21,222	2,738	N/A	4,851	N/A
9/30/2016	20,837	2,444	N/A	3,841	N/A
6/30/2016	20,605	2,466	N/A	3,284	N/A
3/31/2016	20,179	2,319	N/A	2,830	N/A
12/31/2015	19,959	2,408	N/A	2,965	N/A
9/30/2015	19,704	2,359	N/A	3,318	N/A
6/30/2015	19,620	2,059	N/A	3,905	N/A
3/31/2015	19,577	2,192	N/A	4,010	N/A
12/31/2014	19,616	2,391	N/A	4,458	N/A
9/30/2014	20,303	2,690	N/A	4,744	N/A
6/30/2014	21,200	3,392	N/A	5,045	N/A
3/31/2014	22,194	3,865	N/A	5,628	N/A
12/31/2013	23,113	4,685	N/A	5,735	N/A
9/30/2013	23,262	4,785	N/A	5,610	N/A
6/30/2013	22,932	4,908	N/A	5,163	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: LLY(27.2% al año) es superior a la tasa de ahorro (0.6%).

Beneficios vs. Mercado: LLYSe prevé que los beneficios de la empresa (27.2% al año) crezcan más deprisa que el mercado German (13% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de LLY crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: LLYSe prevé que los ingresos de la empresa (15.4% al año) crezcan más deprisa que los del mercado German (4.8% al año).

Ingresos de alto crecimiento: LLYSe prevé que los ingresos de la empresa (15.4% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: LLYSe prevé que la Rentabilidad de los fondos propios de la empresa sea muy elevada dentro de 3 años (63.5%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Eli Lilly Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Eli Lilly and Company Provides Earnings Guidance for the Fiscal Year 2024

Eli Lilly and Company Revises Earnings Guidance for the Year 2023

Eli Lilly and Company Revises Earnings Guidance for the Full Year 2023

Recent updates

Eli Lilly and Company to Report Q1, 2024 Results on Apr 30, 2024

As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal

Now 21% undervalued

SEIU Benefit Plans Master Trust Files a Notice of Exempt Solicitation to Eli Lilly and Company

Eli Lilly and Company Announces Results from A First-Of-Its-Kind Study of Lebrikizumab

Now 21% undervalued

Eli Lilly and Company to Present Donanemab in Early Symptomatic Alzheimer's Disease

Full year 2023 earnings released: EPS: US$5.82 (vs US$6.93 in FY 2022)

Now 22% undervalued

Now 21% undervalued

Philip Johnson to Retire as Eli Lilly and Company's Treasurer

Full year 2023 earnings released: EPS: US$5.80 (vs US$6.93 in FY 2022)

Upcoming dividend of US$1.30 per share at 0.7% yield

Eli Lilly and Company Provides Earnings Guidance for the Fiscal Year 2024

Insufficient new directors

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Eli Lilly and Company to Report Q4, 2023 Results on Feb 06, 2024

Eli Lilly and Company Launches End-To-End Digital Healthcare Experience Through LillyDirect

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

Eli Lilly and Company Announces Updated Clinical Data from the International Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eli Lilly and Company Declares Dividend for the First Quarter of 2024, Payable on March 8, 2024

Eli Lilly and Company Announces Availability of Zepbound (Tirzepatide) Injection

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Jaypirca (Pirtobrutinib) for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphocytic Lymphoma

U.S. Food and Drug Administration Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Upcoming dividend of US$1.13 per share at 0.8% yield

Eli Lilly and Company Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.064 loss per share (vs US$1.61 profit in 3Q 2022)

Eli Lilly and Company Announces FDA Approval for Omvoh (Mirikizumab-Mrkz) Infusion (300 mg/15 mL)/Injection (100 mg/mL)

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer

Eli Lilly and Company to Report Q3, 2023 Results on Nov 02, 2023

Eli Lilly and Company (NYSE:LLY) signed an agreement to acquire Mablink Bioscience S.A.S.

Eli Lilly and Company (NYSE:LLY) signed an agreement to acquire Mablink Bioscience S.A.S.

Eli Lilly and Company Announces Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others for approximately $1.4 billion.

Boehringer Ingelheim and Eli Lilly and Company Announce US FDA Approves Jardiance for Treatment of Adults with Chronic Kidney Disease

Eli Lilly and Company Announces Topline Results from the Libretto-531 Study Evaluating Retevmo

Eli Lilly and Company (NYSE:LLY) acquired Versanis Bio, Inc. from Medicxi Ventures (UK) LLP and others.

Eli Lilly and Company (NYSE:LLY) completed the acquisition of DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders.

Eli Lilly and Company Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$1.95 (vs US$1.06 in 2Q 2022)

Upcoming dividend of US$1.13 per share at 1.0% yield

Eli Lilly and Company Announces Topline Results from the Libretto-431 Study Evaluating Retevmo

Eli Lilly and Company Announces Results of Two Phase 3 Tirzepatide Studies in Adults with Obesity or Overweight with Weight-Related Comorbidities, Excluding Type 2 Diabetes

Eli Lilly and Company to Report Q2, 2023 Results on Aug 08, 2023

Eli Lilly and Company Presents Full Results from the Phase 3 Trial of Donanemab

Eli Lilly and Company (NYSE:LLY) enter into a definitive agreement to acquire Versanis Bio, Inc. from Medicxi Ventures (UK) LLP and others for approximately $1.925 billion.

Eli Lilly and Company Announces New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Eli Lilly and Company (NYSE:LLY) acquired unknown minority stake in Eli Lilly and Company (NYSE:LLY) from Heidelberg Pharma GmbH.

Eli Lilly and Company Declares Third-Quarter 2023 Dividend, Payable on September 8, 2023

Eli Lilly and Company(NYSE:LLY) dropped from Russell Top 200 Value Index

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from RA Capital Healthcare Fund, L.P. and RA Capital Healthcare Fund, L.P., funds managed by RA Capital Management, L.P., J. Kevin Judice and others for $2.3 billion.

Eli Lilly and Company Announces First-Of-Its-Kind Head-To-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Attorneys At Hagens Berman and Carella Byrne Cecchi Olstein Brody & Agnello Announces Settlement Worth in Excess of $500 Million Reached in Insulin Pricing Class-Action Lawsuit

Eli Lilly and Company Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis

Eli Lilly and Company Announces Positive Results of the Trailblazer-Alz 2 Phase 3 Study

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento